What question did this study set out to answer?

The study aims to assess the feasibility of a mobile application for delivering geriatric assessment and communication support among older adults with cancer.

January 24, 2026Open Access

Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)

Key Points

The study aims to assess the feasibility of a mobile application for delivering geriatric assessment and communication support among older adults with cancer.
Multicentre, open-label, pilot randomised controlled trial design.
Participants aged ≥70 years with solid cancer or lymphoma initiating or changing systemic therapy.
Baseline geriatric assessment conducted for all participants.
Randomisation into mobile application intervention group or usual care group.
Primary endpoint focused on intervention completion rates.
Detailed findings not provided yet, as the trial is ongoing.
The emphasis is on evaluating participant completion rates of the intervention components.

Abstract

Introduction Older adults with cancer have ageing-related vulnerabilities that influence their treatment tolerance and decision-making. In our previous randomised controlled trial (MAPLE), integrating geriatric assessment (GA) with communication support using a question prompt list (QPL), delivered by trained intervention providers, facilitated patient–oncologist communication, increased implementation of GA-guided management (GAM) and improved patient outcomes. However, its widespread adoption has been limited by the need for trained personnel and dedicated time. To enhance scalability and sustainability, we developed a mobile application-based intervention to deliver GAM and communication support. This MAPLE2 study aims to evaluate the feasibility of the intervention using this mobile application-based GA and QPL among older adults with cancer. Methods and analysis This multicentre, open-label, pilot randomised controlled trial will be conducted at two academic hospitals in Japan. Patients aged≥70 years with solid cancer or lymphoma initiating or changing systemic therapy will undergo baseline GA. Patients with any GA impairment will be randomised to receive either (1) a mobile application-based intervention providing feedback of GA summary with tailored GAM recommendations and QPL or (2) usual care. The primary endpoint is the proportion of participants who complete all of the following interventions using the mobile application: (1) self-administered GA, (2) receipt of the tailored GAM recommendations and QPL and (3) confirmation that their oncologists review the tailored GAM recommendations and QPL at subsequent visits. Forty participants are planned to be enrolled. Ethics and dissemination The study has been approved by the Institutional Review Board of the National Cancer Center, Japan (approval number: 2025-089). Written informed consent will be obtained from all participants. Results will be presented at academic conferences and published in peer-reviewed journals. Trial status Recruitment has been initiated from 8 September 2025 and is planned to be completed by 31 August 2026, with a follow-up period by 31 August 2027. Trial registration number UMIN000058887

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper